M

Mass General Brigham

Early-stage life science venture investor

Physician Assistant - Endocrine

Full-TimePosted on 10/26/2026
$135.7k - $173.9k/yr+ Differentials + Premiums + Bonuses
Mid
Master's
Boston, MA, USA
HybridHybrid work at 221 Longwood Avenue.
Medical, Clinical & VeterinaryAdvanced Practice Providers

About the job

Requirements
  • A master's degree from an accredited Physician Assistant program is required.
  • A current, valid Massachusetts Physician Assistant license is required.
  • Current NCCPA certification (PA-C) is required.
  • Ability to work with a variety of information systems and databases, including MS Word, PowerPoint, Access, and electronic health records.
  • Knowledge of and commitment to team-based care principles and awareness of local, regional, and national trends in chronic disease care redesign and transformation.
  • Expert clinical knowledge and technical skills to perform all aspects of the role.
  • Strong organizational skills.
  • Project management ability and skills.
  • Ability to manage meetings to encourage participation and achieve results.
  • Ability to manage time and resources effectively to meet program deadlines and objectives.
  • Problem-solving ability and data management and analysis skills.
  • Ability to perform in fast-paced office, clinical, and patient home settings.
  • Knowledge of evidence-based practice and ability to ensure that clinical practice is evidence-based.
  • Ability to function clinically as both an autonomous provider and a member of an interdisciplinary team.
  • Demonstrated ability to work collaboratively with clinical and administrative staff and form strong partnerships.
  • Ability to function at a high professional and clinical level.
  • Knowledge of Universal Precautions and proper use of surgical sharp instruments may be required.
  • The position may require heavy lifting of equipment and patients.
  • The position may require standing or walking for a large portion of the workday.
Responsibilities
  • Provide direct care independently and in collaboration with other providers while maintaining a panel of patients.
  • Provide direct care, counseling, and teaching to patients.
  • Perform physical examinations and provide preventive health measures appropriate to patient needs.
  • Order, interpret, and evaluate laboratory and diagnostic tests to assess clinical problems and health care needs.
  • Arrange appropriate plans of care and follow-up based on diagnostic, laboratory, and physical assessment findings, and seek consultation as appropriate.
  • Order medications and write prescriptions in accordance with organizational and regulatory policies and procedures.
  • Record pertinent patient care findings in the electronic medical record.
  • Set priorities for efficient patient care management that reflects evidence-based practice and cost-effective use of time, human resources, supplies, and equipment.
  • Coordinate and communicate patient care information with providers, the clinical team, and other health care professionals.
  • Incorporate health maintenance, prevention, and promotion into daily practice through patient education and counseling.
  • Support patients and families in self-care management by providing information, tools, and resources.
  • Help staff, patients, and families use community and hospital resources effectively.
  • Participate in performance improvement activities, use performance and patient outcome data for continuous quality improvement, and contribute to improved care structures, processes, and systems.
  • Collaborate with physicians, physician assistants, and the interdisciplinary team to refine team goals and objectives and continuously improve care delivery.
  • Analyze, interpret, and present team-based care results to organizational, departmental, practice, and nursing leaders, colleagues, and staff as appropriate.
  • Translate themes identified through quality monitoring and evaluation into the care model and clinical practice of the interdisciplinary team.
  • See patients with hypothyroidism to monitor treatment response and adjust thyroid hormone doses.
  • Conduct virtual visits with pregnant patients with hypothyroidism during each trimester to monitor treatment response and adjust thyroid hormone doses.
  • See patients treated with radioactive iodine for hyperthyroidism to monitor post-treatment thyroid hormone levels.
  • See patients with low-risk thyroid cancer to review imaging studies and blood tests for recurrence monitoring.
  • Assess thyroid ultrasound results to determine which patients with nodular thyroid disease need initial or repeat fine needle aspiration biopsies.
  • See patients with osteoporosis who have started bisphosphonate treatment to assess adherence and side effects.
  • Conduct virtual visits with patients treated for osteoporosis with bisphosphonates or other antiresorptive agents to monitor status, adherence, and side effects.
  • See patients with primary hyperparathyroidism after parathyroidectomy to monitor post-treatment calcium and PTH levels.
  • See patients with primary adrenal insufficiency on stable glucocorticoid and mineralocorticoid replacement to monitor treatment response.
  • See patients with steroid-induced adrenal insufficiency to monitor status while glucocorticoids are tapered.
  • See patients with hypertension for blood pressure checks after antihypertensive regimens are modified or adjusted.
  • See patients who have started estrogen replacement therapy for menopausal vasomotor symptoms to monitor status, side effects, and appropriate dynamic endocrine testing.
  • See patients with other endocrine disorders as appropriate.
Desired Qualifications
  • A doctoral degree (DMSc or equivalent) is preferred.
  • Certified Diabetes Educator certification is preferred.
  • Three or more years of Physician Assistant experience in endocrinology, primary care, or chronic disease management is strongly preferred.
  • Three or more years of clinical experience in a hospital or community-based practice setting is strongly preferred, with experience in both settings strongly preferred.
  • Demonstrated knowledge of hospital-based and community-based care is strongly preferred.
  • Experience working in large, complex health care organizations.
  • Experience working with a diverse patient population.

About the company

Mass General Brigham Ventures funds early-stage life science ideas arising from Mass General Brigham’s research network. It provides first access to deal flow and proprietary rights, backing the formation and growth of new companies and technologies. It uses capital and support to help translate bold innovations into drugs and medical technologies that improve patient outcomes worldwide.

Company Size

1-10

Company Stage

N/A

Total Funding

$1.9B

Headquarters

Cambridge, Massachusetts

Founded

2008

Get referred to Mass General Brigham

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Mass General Brigham reported $15 million operating income through June 30, 2026.
  • Outpatient growth and higher-acuity inpatient volumes drove 7% revenue growth in Q3 FY26.
  • Abcuro's 2026 financing extends a potential registrational trial, validating MGB Ventures sourcing.

What critics are saying

  • Brigham nurses authorized an indefinite strike on September 24, 2026; operations face disruption.
  • MGB refused negotiations after July strikes and lockouts, deepening staffing instability into 2027.
  • The September 2026 antidiscrimination case and website-data settlement reinforce litigation overhangs.

What makes Mass General Brigham unique

  • Mass General Brigham controls flagship Boston hospitals and a research-to-venture pipeline.
  • MGB Ventures backed Abcuro's $66 million Series D in August 2026.
  • Its $22.8 billion 2025 operating revenue funds clinical, academic, and commercialization depth.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • Flexible Work Hours
  • Remote Work Options
  • Hybrid Work Options
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Family Planning Benefits
  • Fertility Treatment Support

Company News

Business Wire
Oct 25th, 2026
Nocion Therapeutics Extends Series B Financing to $93 Million to Support Late-Stage Development of Taplucainium in Chronic Cough

Nocion Therapeutics, Inc. today announced that it has raised $23 million from existing investors in an extension of its Series B, bringing the total amount o...

PR Newswire
Oct 1st, 2026
Mass General Brigham postpones annual summit after nurses plan picket over $2.3B hospital system refusing fair contracts

Mass General Brigham has postponed its annual summit after nurses and clinicians represented by the Massachusetts Nurses Association issued a picket notice for the 7 October event in Somerville. The postponement follows a 93% strike authorisation vote by Brigham and Women's Hospital nurses and protests against MGB executives. MGB nurses and clinicians have been campaigning against the hospital system following strikes and a lockout in July. Brigham nurses are seeking contract improvements including limits on temporary nurses, affordable health insurance, and fair compensation. MGB Home Care clinicians are negotiating their first union contract. MGB reported $22.8 billion in operating revenue and $2.39 billion in profits for fiscal year 2025. The system has refused to return to negotiations since August.

ABCuro
Aug 18th, 2026
Abcuro announces $66 million Series D financing to advance its first-in-class Medicine in development for Inclusion Body Myositis.

Abcuro announces $66 million Series D financing to advance its first-in-class Medicine in development for Inclusion Body Myositis. * Proceeds to support a potentially registrational clinical study in less severe inclusion body myositis (IBM) patients expected to begin in Q4 2026 and report top line results in 2H 2028 * Ulviprubart showed a trend toward clinically meaningful slowing of disease progression in patients with less severe IBM in the previous Phase 2/3 MUSCLE study * Series D financing led by New Leaf Venture Partners, joined by Abcuro's existing investors and new investor Rock Springs Capital Newton, Massachusetts, August 18, 2026 - Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases through precise modulation of cytotoxic T cells, today announced the closing of a $66 million Series D financing led by current investor New Leaf Venture Partners with participation of existing investors including funds managed by abrdn Inc., Bain Capital Life Sciences, Samsara BioCapital, Redmile Group, Mass General Brigham Ventures, RA Capital Management, Pontifax, Sanofi Ventures, Foresite Capital, NEA, Eurofarma Ventures, Kaitai Capital, Soleus Capital, Nancy Chang, Shang Bay and joining the round is Rock Springs Capital. Proceeds from the Series D financing will support a new potentially registrational clinical study of ulviprubart, a first-in-class monoclonal antibody targeting killer cell lectin like receptor G1 (KLRG1), for the treatment of patients with less severe IBM. Abcuro has been in discussions with the U.S. Food and Drug Administration (FDA) and expects to initiate the new study in the fourth quarter of this year. Assuming positive results from the clinical study, Abcuro plans to file a biologics license application (BLA). "We are pleased to have this opportunity to further evaluate ulviprubart in patients with IBM, a devastating progressive disease," said Alex Martin, Chief Executive Officer of Abcuro. "We have begun preparations to initiate a clinical trial in the fourth quarter of 2026 as we continue our work to develop an effective treatment option in an indication where there is no approved therapy. We remain dedicated to the IBM community and thank our investors who share our conviction in ulviprubart's potential." Results from the recent Phase 2/3 MUSCLE study of ulviprubart in patients with IBM were presented at the 6th Global Conference on Myositis (GCOM) meeting in March 2026. The clinical data, while not statistically significant, showed a trend toward slowing of disease progression relative to placebo as measured by IBMFRS in the overall patient population, including a 50% slowing of disease progression in a pre-defined analysis of less severe IBM patients with IBMFRS >29. Ulviprubart was also shown to have a favorable safety and tolerability profile compared to placebo. "The MUSCLE study provided encouraging data in a pre-defined analysis of patients with less severe disease, underscoring ulviprubart's unique mechanism of targeting highly differentiated cytotoxic T cells expressing KLRG1," said Namita Goyal, MD, Chief of the Neuromuscular Division at the University of California, Irvine School of Medicine. "IBM continues to be a disabling, progressive disease with no approved treatment, affecting tens of thousands of patients around the world. Ulviprubart demonstrated clear and meaningful slowing of disease progression in less severe disease, offering real hope to patients, care partners, and the physicians who treat them." "There is a significant unmet need for an approved treatment for IBM. The expertise and persistence of the Abcuro team to understand this disease and the role ulviprubart may have in targeting these cytotoxic T cells that are associated with muscle destruction was key to our continued investment of the company. We are excited to work closely with the company as it moves forward in this next chapter," said Ron Hunt, Co-Founder and Managing Director of New Leaf Venture Partners. About Ulviprubart Ulviprubart is a first-in-class, potent, monoclonal antibody that targets pathogenic T cells that express killer cell lectin-like receptor G1 (KLRG1) on their cell surface, referred to as KLRG1+ T cells. Ulviprubart is designed to selectively target and deplete well-differentiated cytotoxic KLRG1+ T cells where KLRG1 is highly expressed, while sparing other immune cells, which may offer improvements in safety and tolerability as compared to other T cell depleting approaches. About Inclusion Body Myositis (IBM) IBM is a rare, debilitating and relentlessly progressive chronic autoimmune muscle disease with no approved pharmacologic treatments and a significant unmet need. It is mediated by highly differentiated T cells that are chronically or aberrantly overstimulated and can have detrimental long-term effects including destruction of healthy muscle tissue. People living with IBM progressively lose muscle function, including loss of grip, dexterity and mobility. Based on published epidemiology literature, the ICD-10 code for IBM and an estimate for those misdiagnosed or undiagnosed, Abcuro estimate there are approximately 40,000 patients diagnosed with IBM in the United States and Abcuro estimate the prevalence of IBM to be approximately 35,000 patients across major European countries and Japan. Abcuro estimate that patients with less severe disease represent nearly 50% of the overall IBM patient population. About Abcuro Abcuro is a clinical stage biotechnology company developing potentially first-in-class immunotherapies designed to benefit people living with debilitating and progressive rare autoimmune diseases and for other indications where certain cytotoxic T cells are pathogenic. Abcuro believe that by selectively targeting and depleting highly cytotoxic T cells, which are key drivers of chronic inflammation and damage, Abcuro can advance its mission to deliver potentially life-transforming, disease-modifying therapies to patients facing these devastating conditions. The company's lead program, ulviprubart, is currently being evaluated in inclusion body myositis (IBM). For more information, visit Abcuro on LinkedIn and at abcuro.com.

Claris Bio
Jul 29th, 2026
07-28-2026 Press Releases from Claris Bio

Latest Press Releases from Claris Bio.

Fierce Healthcare
Jun 15th, 2026
InStride Health lands $30M series C to expand pediatric mental health services

InStride Health, a provider of virtual specialty mental healthcare for children and young adults, has raised $30 million in Series C funding led by Echo Health Ventures and FMZ Ventures. Existing investors including .406 Ventures, General Catalyst and Mass General Brigham Ventures also participated. Founded in 2021, InStride offers insurance-based treatment for anxiety and obsessive-compulsive disorder in patients aged seven to 24. The company pairs each patient with a care team comprising a psychiatrist, therapist and exposure coach, providing support through text and a mobile application. InStride has treated 5,000 patients across 17 states, primarily on the East Coast and Texas. The company published data showing 97% of patients demonstrated clinical improvement, with a 53% average reduction in anxiety scores. The funding will support expansion into new markets and strengthen payer partnerships.